Furthermore, we showed that NAM, as a class III histone deacetylase inhibitor, could inhibit the deacetylase activity of CobB, thereby increasing the acetylation level of the FomA and reducing its binding ability to CRC cells. Here, STAC3 is linked to colorectal carcinoma.